Fig. 4: Paclitaxel increases the sensitivity towards BH3 mimetics. | Cell Death & Disease

Fig. 4: Paclitaxel increases the sensitivity towards BH3 mimetics.

From: The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents

Fig. 4

A The indicated cell lines were treated with 50 nM paclitaxel alone or in combination with 1 µM of BH3mimetics for 48 h. B–E TNBC cell lines were treated with graded concentrations of BH3-mimetics in combination with a predetermined fixed concentration of paclitaxel for 48 h. Metabolic activity was calculated by setting the metabolic activity in relation to the DMSO control. Heatmaps show mean values of metabolic activity ranging from 0 to 100% as assessed by MTT-assay. A All cell lines (n = 3–4), B MDA-MB-231 (n = 6), C HS-578-T (n = 4), D Cal-51 (n = 6), E BT20 (n = 6).

Back to article page